Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Promedior Begins Phase 2a Trial of PRM-151

September 7, 2010 8:17 am | News | Comments

Promedior, Inc. has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.

TOPICS:

Orexigen Signs Billion Dollar Deal With Takeda

September 7, 2010 8:14 am | News | Comments

Orexigen Therapeutics Inc. has signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals. Under the deal, Orexigen will receive $50 million upfront from Takeda, Japan's largest drugmaker.

TOPICS:

Abbott Halts Influvac Sale

September 7, 2010 8:11 am | by Matthew Perrone | News | Comments

Drug and medical device firm Abbott Laboratories said it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.

TOPICS:
Advertisement

Blood Pressure Medicine Not Always Suited to User

September 7, 2010 8:02 am | by Lauran Neergard | News | Comments

It's hard to predict which pills will best lower which patient's high blood pressure, but researchers are hunting ways to better personalize therapy - perhaps even using a blood test. The work is controversial, challenging today's usual approach to treating the hypertension that plagues nearly one in three U.S. adults.

TOPICS:

Bone-Strengthening Drug May Raise Risk of Cancer

September 7, 2010 7:57 am | by Maria Cheng | News | Comments

People who take bone-strengthening drugs for several years may have a slightly higher risk of esophageal cancer, a new study suggests. The findings are in contrast to another recent study that used the same database of 80,000 patients and found no link between the drugs and esophageal cancer.

TOPICS:

WHO Wants Faster Flu Vaccine Production

September 7, 2010 7:54 am | News | Comments

The vaccine used to contain the recent swine flu pandemic was effective, but health authorities will need to ramp up the speed and volume of production during the next global outbreak, a World Health Organization official said.

TOPICS:

Feds Hold Off On ProAmatine Withdrawal

September 7, 2010 7:49 am | News | Comments

Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

TOPICS:

British Regulators Want Avandia Yanked

September 7, 2010 7:36 am | News | Comments

GlaxoSmithKline's controversial diabetes pill Avandia should be pulled from the U.K. market because of concerns that the drug can increase the risk of heart attacks, British drug regulators said.

TOPICS:
Advertisement

Japan Confirms Presence of Superbug Gene

September 7, 2010 7:34 am | by Shino Yuasa | News | Comments

Japan has confirmed the nation's first case of a new gene in bacteria that allows the microorganisms to become drug-resistant superbugs, detected in a man who had medical treatment in India, a Health Ministry official said.

TOPICS:

Multipurpose Filters

September 2, 2010 9:03 am | Product Releases | Comments

Meissner’s Steridyne 50 (PVDF) and Ultradyne 50 (PTFE) are multipurpose 50 mm filters for small volume venting, gas and solvent filtration. The filters are offered with stepped hose barb inlet/outlet connections.

TOPICS:

Mammalian Cell Lines

September 2, 2010 8:59 am | Product Releases | Comments

Sigma Life Science, the biological products and research services business of Sigma-Aldrich Corporation, announced the global release of a pioneering range of engineered mammalian cell lines.

TOPICS:

First Genetically Engineered Rat Derived From ES Cells

September 2, 2010 8:41 am | News | Comments

StemCells, Inc. announced that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem cells.

TOPICS:

MorphoSys And Absynth Sign Collaboration

September 2, 2010 8:33 am | News | Comments

MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus).

TOPICS:

Abnormal Weight A Colon Cancer Risk Factor

September 2, 2010 8:28 am | News | Comments

Postmenopausal women diagnosed with colon cancer may be at increased risk of death if they fail to maintain a healthy body weight before cancer diagnosis, according to a study published in a journal of the American Association for Cancer Research.

TOPICS:

NIH Awards Grants for Biomedical Research In Space

September 2, 2010 8:24 am | News | Comments

The National Institutes of Health announced today that it has awarded the first new grants under the Biomedical Research on the International Space Station (BioMed-ISS) initiative, a collaborative effort between NIH and NASA.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading